SEARCH:   Advanced

Blood, 1 February 2004, Vol. 103, No. 3, pp. 790-795. Prepublished online as a Blood First Edition Paper on October 2, 2003; DOI 10.1182/blood-2003-07-2344. This Article Full Text (PDF) All Versions of this Article: 2003-07-2344v1 103/3/790    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bethge, W. A Articles by Sandmaier, B. M Search for Related Content PubMed PubMed Citation Articles by Bethge, W. A Articles by Sandmaier, B. M Related Collections Related Letter in Blood Online Social Bookmarking                   What's this? Submitted July 11, 2003 Accepted September 22, 2003 Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning Wolfgang A Bethge, Ute Hegenbart, Monic J Stuart, Barry E Storer, Michael B Maris, Mary E D Flowers, David G Maloney, Thomas Chauncey, Benedetto Bruno, Ed Agura, Stephen J Forman, Karl G Blume, Dietger Niederwieser, Rainer Storb, and Brenda M Sandmaier* Fred Hutchinson Cancer Research Center, Seattle, WA, USA; University of Washington, Seattle, WA, USA University of Leipzig, Leipzig, Germany Stanford University, Stanford, CA, USA Veterans Administration Medical Center, Seattle, WA, USA University of Torino, Turin, Italy Baylor University, Dallas, TX, USA City of Hope National Medical Center, Duarte, CA, USA * Corresponding author; email: bsandmai{at}fhcrc.org. This study retrospectively analyzed data from 446 patients given hematopoietic cell transplantation (HCT) from HLA-matched related or unrelated donors after conditioning with 2 Gy total body irradiation with or without fludarabine and postgrafting immunosuppression with mycophenolate mofetil and cyclosporine. Fifty-three of 446 patients received DLI with a median CD3-dose of 1x107 cells/kg. Their diagnoses included myelodysplastic syndrome (n=10), acute leukemia (n=10), chronic leukemia (n=11), multiple myeloma (n=9), lymphoma (n=9) and solid tumors (n=4). Patients received DLI for persistent disease (n=8), disease relapse (n=17), progressive disease (n=12), low donor chimerism with disease (n=11) or low chimerism with disease remission (n=5). Seventeen of the 53 patients (32%) are alive with a median follow-up of 30 months; five in complete remission (CR), 2 in partial remission (PR) and 10 with stable or progressive disease. Nine of 53 patients (17%) developed grades II-IV acute graft-versus-host disease. Of 48 patients receiving DLI for treatment of disease, 7 achieved CR and 5 PR, with an overall response rate of 25%. Six of 16 patients who received DLI for chimerism had increases in donor chimerism leading to sustained engraftment while 10 eventually rejected their grafts. In conclusion, DLI is a potential treatment strategy for patients with persistent, relapsed or progressive disease after nonmyeloablative HCT with acceptable toxicity. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: Donor lymphocyte infusions after reduced intensity conditioning allogeneic transplantation: what we need to know David I. Marks, Anne Parker, and Stephen P. Robinson Blood 2004 104: 295-296. [Full Text] [PDF] This article has been cited by other articles: A. Ghosh, W. Koestner, M. Hapke, V. Schlaphoff, F. Langer, R. Baumann, C. Koenecke, M. Cornberg, K. Welte, B. R. Blazar, et al. Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras Blood, April 30, 2009; 113(18): 4440 - 4448. [Abstract] [Full Text] [PDF] D. Sangiolo, E. Martinuzzi, M. Todorovic, K. Vitaggio, A. Vallario, N. Jordaney, F. Carnevale-Schianca, A. Capaldi, M. Geuna, L. Casorzo, et al. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers Int. Immunol., July 1, 2008; 20(7): 841 - 848. [Abstract] [Full Text] [PDF] M. Eto, Y. Kamiryo, A. Takeuchi, M. Harano, K. Tatsugami, M. Harada, K. Kiyoshima, M. Hamaguchi, T. Teshima, M. Tsuneyoshi, et al. Posttransplant Administration of Cyclophosphamide and Donor Lymphocyte Infusion Induces Potent Antitumor Immunity to Solid Tumor Clin. Cancer Res., May 1, 2008; 14(9): 2833 - 2840. [Abstract] [Full Text] [PDF] R. Chakraverty and M. Sykes The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia Blood, July 1, 2007; 110(1): 9 - 17. [Abstract] [Full Text] [PDF] N. Durakovic, V. Radojcic, M. Skarica, K. B. Bezak, J. D. Powell, E. J. Fuchs, and L. Luznik Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse Blood, May 15, 2007; 109(10): 4564 - 4574. [Abstract] [Full Text] [PDF] M. Eto, M. Harano, K. Tatsugami, M. Harada, Y. Kamiryo, K. Kiyoshima, M. Hamaguchi, M. Tsuneyoshi, Y. Yoshikai, and S. Naito Cyclophosphamide-Using Nonmyeloablative Allogeneic Cell Therapy against Renal Cancer with a Reduced Risk of Graft-versus-Host Disease Clin. Cancer Res., February 1, 2007; 13(3): 1029 - 1035. [Abstract] [Full Text] [PDF] F. Baron, R. Storb, B. E. Storer, M. B. Maris, D. Niederwieser, J. A. Shizuru, T. R. Chauncey, B. Bruno, S. J. Forman, P. A. McSweeney, et al. Factors Associated With Outcomes in Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning After Failed Myeloablative Hematopoietic Cell Transplantation J. Clin. Oncol., September 1, 2006; 24(25): 4150 - 4157. [Abstract] [Full Text] [PDF] M. Harano, M. Eto, T. Iwai, K. Tatsugami, K. Kiyoshima, Y. Kamiryo, M. Tsuneyoshi, Y. Yoshikai, and S. Naito Renal Cancer Treatment with Low Levels of Mixed Chimerism Induced by Nonmyeloablative Regimen Using Cyclophosphamide in Mice Cancer Res., November 1, 2005; 65(21): 10032 - 10040. [Abstract] [Full Text] [PDF] F. Baron, M. B. Maris, B. M. Sandmaier, B. E. Storer, M. Sorror, R. Diaconescu, A. E. Woolfrey, T. R. Chauncey, M. E.D. Flowers, M. Mielcarek, et al. Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning J. Clin. Oncol., March 20, 2005; 23(9): 1993 - 2003. [Abstract] [Full Text] [PDF] B. M. Sandmaier, D. G. Maloney, M. B. Maris, T. R. Chauncey, M. Pulsipher, W. Bethge, M.-T. Little, and R. Storb Conversion of Low Donor Chimerism Following Nonmyeloablative Conditioning for Hematopoietic Cell Transplantation (HCT) Using Pentostatin and Donor Lymphocyte Infusion (DLI). Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 186 - 186. [Abstract] D. I. Marks, A. Parker, and S. P. Robinson Donor lymphocyte infusions after reduced intensity conditioning allogeneic transplantation: what we need to know Blood, July 1, 2004; 104(1): 295 - 296. [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020